Drug Search Results
More Filters [+]

COV-795

Alternative Names: cov-795, cov795, cov 795, mnk795
Latest Update: 2020-09-17
Latest Update Note: Clinical Trial Update

Product Description

MNK-795 is an investigational, extended-release oral formulation of oxycodone and acetaminophen that has been studiedfor the management of moderate to severe acute pain where the use of an opioid analgesic is appropriate.

Mechanisms of Action: No Mechanism

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Mallinckrodt
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for COV-795

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Low Back Pain|Bunion|Pain, Postoperative|Osteoarthritis

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

COV15000182

P3

Completed

Bunion|Pain, Postoperative

2012-08-01

COV15000181

P3

Completed

Low Back Pain|Osteoarthritis

2012-06-18

Recent News Events

Date

Type

Title